Rebion Information

Based on years of research and trials at major medical institutions, Rebion has harnessed the breakthrough Neural Performance Scanning (NPS) to precisely measure signal patterns that return from the brain, instantly determining if faulty signal processing is present. NPS portable point-of-care devices provide previously unavailable information for fast and impactful triage, making early disease detection, intervention and customized treatment more accessible. The company was founded by David Hunter, MD PhD, Ophthalmologist-in-Chief at Boston Children’s Hospital and FDA cleared in 2016. After more than 15 years of R&D and clinical testing, Dr. Hunter co-developed this technology with Johns Hopkins and Harvard. Patients can now be confidently referred for further diagnosis and treatment, improving health outcomes and reducing treatment costs. Rebion provides a “Window to the Brain” to identify and help manage life-altering conditions that manifest from functional impairment in the brain.